These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10967267)

  • 1. Active CMV infection before lung transplantation: risk factors and clinical implications.
    Milstone AP; Brumble LM; Loyd JE; Ely EW; Roberts JR; Pierson RN; Dummer JS
    J Heart Lung Transplant; 2000 Aug; 19(8):744-50. PubMed ID: 10967267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients.
    Bhorade SM; Lurain NS; Jordan A; Leischner J; Villanueva J; Durazo R; Creech S; Vigneswaran WT; Garrity ER
    J Heart Lung Transplant; 2002 Dec; 21(12):1274-82. PubMed ID: 12490272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation.
    Kruger RM; Shannon WD; Arens MQ; Lynch JP; Storch GA; Trulock EP
    Transplantation; 1999 Nov; 68(9):1272-9. PubMed ID: 10573063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
    Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.
    Bonaros NE; Kocher A; Dunkler D; Grimm M; Zuckermann A; Ankersmit J; Ehrlich M; Wolner E; Laufer G
    Transplantation; 2004 Mar; 77(6):890-7. PubMed ID: 15077033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
    Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid T cell repopulation after rabbit anti-thymocyte globulin (rATG) treatment is driven mainly by cytomegalovirus.
    Havenith SH; Remmerswaal EB; Bemelman FJ; Yong SL; van Donselaar-van der Pant KA; van Lier RA; Ten Berge IJ
    Clin Exp Immunol; 2012 Sep; 169(3):292-301. PubMed ID: 22861369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.
    Huurman VA; Kalpoe JS; van de Linde P; Vaessen N; Ringers J; Kroes AC; Roep BO; De Fijter JW
    Diabetes Care; 2006 Apr; 29(4):842-7. PubMed ID: 16567825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basiliximab as an alternative to antithymocyte globulin for early immunosuppression in lung transplantation.
    Clinckart F; Bulpa P; Jamart J; Eucher P; Delaunois L; Evrard P
    Transplant Proc; 2009 Mar; 41(2):607-9. PubMed ID: 19328937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic significance of positive CMV cultures during surveillance of renal transplant recipients.
    Pillay D; Ali AA; Liu SF; Kops E; Sweny P; Griffiths PD
    Transplantation; 1993 Jul; 56(1):103-8. PubMed ID: 8392760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of ganciclovir prophylaxis on cytomegalovirus infection in recipients of cadaveric renal allografts.
    Ram Peddi V; Hariharan S; Schroeder TJ; First MR
    Nephron; 1997; 76(1):49-55. PubMed ID: 9171300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
    Ahsan N; Holman MJ; Yang HC
    Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
    Fricke L; Steinhoff J; Hartwig-Weber I; Bein G
    Dtsch Med Wochenschr; 1997 May; 122(18):565-71. PubMed ID: 9190308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation.
    Goodrich JM; Mori M; Gleaves CA; Du Mond C; Cays M; Ebeling DF; Buhles WC; DeArmond B; Meyers JD
    N Engl J Med; 1991 Dec; 325(23):1601-7. PubMed ID: 1658652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
    Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin.
    Gutiérrez CA; Chaparro C; Krajden M; Winton T; Kesten S
    Chest; 1998 Apr; 113(4):924-32. PubMed ID: 9554627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus-related complications in human hand transplantation.
    Schneeberger S; Lucchina S; Lanzetta M; Brandacher G; Bösmüller C; Steurer W; Baldanti F; Dezza C; Margreiter R; Bonatti H
    Transplantation; 2005 Aug; 80(4):441-7. PubMed ID: 16123716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
    Turgeon N; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH
    Transplantation; 1998 Dec; 66(12):1780-6. PubMed ID: 9884276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group.
    Schmidt GM; Horak DA; Niland JC; Duncan SR; Forman SJ; Zaia JA
    N Engl J Med; 1991 Apr; 324(15):1005-11. PubMed ID: 1848679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.